185 related articles for article (PubMed ID: 35219151)
1. Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
Hegde PV; Howe MD; Zimmerman MD; Boshoff HIM; Sharma S; Remache B; Jia Z; Pan Y; Baughn AD; Dartois V; Aldrich CC
Eur J Med Chem; 2022 Mar; 232():114201. PubMed ID: 35219151
[TBL] [Abstract][Full Text] [Related]
2. Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.
Minato Y; Thiede JM; Kordus SL; McKlveen EJ; Turman BJ; Baughn AD
Antimicrob Agents Chemother; 2015 Sep; 59(9):5097-106. PubMed ID: 26033719
[TBL] [Abstract][Full Text] [Related]
3. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.
Sy SK; de Kock L; Diacon AH; Werely CJ; Xia H; Rosenkranz B; van der Merwe L; Donald PR
Antimicrob Agents Chemother; 2015 Jul; 59(7):4129-38. PubMed ID: 25963985
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
de Kock L; Sy SK; Rosenkranz B; Diacon AH; Prescott K; Hernandez KR; Yu M; Derendorf H; Donald PR
Antimicrob Agents Chemother; 2014 Oct; 58(10):6242-50. PubMed ID: 25114132
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance.
Adams KT; Donald PR; Abulfathi AA; Diacon AH; Stander MA; Reuter H
J Clin Pharmacol; 2020 Apr; 60(4):489-494. PubMed ID: 31682027
[TBL] [Abstract][Full Text] [Related]
6. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis.
Chakraborty S; Gruber T; Barry CE; Boshoff HI; Rhee KY
Science; 2013 Jan; 339(6115):88-91. PubMed ID: 23118010
[TBL] [Abstract][Full Text] [Related]
7. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.
Zheng J; Rubin EJ; Bifani P; Mathys V; Lim V; Au M; Jang J; Nam J; Dick T; Walker JR; Pethe K; Camacho LR
J Biol Chem; 2013 Aug; 288(32):23447-56. PubMed ID: 23779105
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Chirehwa M; Winckler JL; Mao J; Draper HR; Wiesner L; Norman J; McIlleron H; Donald PR; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0226421. PubMed ID: 35506699
[TBL] [Abstract][Full Text] [Related]
9. Methionine Antagonizes
Howe MD; Kordus SL; Cole MS; Bauman AA; Aldrich CC; Baughn AD; Minato Y
Front Cell Infect Microbiol; 2018; 8():399. PubMed ID: 30483484
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic evaluation of para-aminosalicylic acid granules.
Peloquin CA; Henshaw TL; Huitt GA; Berning SE; Nitta AT; James GT
Pharmacotherapy; 1994; 14(1):40-6. PubMed ID: 8159600
[TBL] [Abstract][Full Text] [Related]
11. [Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism].
Mizutani H; Horiba M; Shindoh J; Kimura T; Son M; Wakahara K
Kekkaku; 2001 Oct; 76(10):667-72. PubMed ID: 11712388
[TBL] [Abstract][Full Text] [Related]
12. Successful oral desensitization to i.v. para-aminosalicylic acid (PAS) using encapsulated PAS dry substance.
Vesenbeckh SM; Becker J; Huhnt C; Karras B; Bauer TT; Mauch H; Rüssmann H; Schönfeld N
Infection; 2012 Apr; 40(2):199-202. PubMed ID: 21833615
[TBL] [Abstract][Full Text] [Related]
13. Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens.
Abulfathi AA; Assawasuwannakit P; Donald PR; Diacon AH; Reuter H; Svensson EM
Eur J Clin Pharmacol; 2020 Nov; 76(11):1557-1565. PubMed ID: 32588106
[TBL] [Abstract][Full Text] [Related]
14. New prodrugs against tuberculosis.
Mori G; Chiarelli LR; Riccardi G; Pasca MR
Drug Discov Today; 2017 Mar; 22(3):519-525. PubMed ID: 27649942
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium tuberculosis Arylamine N-Acetyltransferase Acetylates and Thus Inactivates para-Aminosalicylic Acid.
Wang X; Yang S; Gu J; Deng J
Antimicrob Agents Chemother; 2016 Dec; 60(12):7505-7508. PubMed ID: 27671064
[TBL] [Abstract][Full Text] [Related]
16. Para-aminosalicylic acid (PAS) desensitization review in a case of multidrug-resistant pulmonary tuberculosis.
Wilson JW; Kelkar P; Frigas E
Int J Tuberc Lung Dis; 2003 May; 7(5):493-7. PubMed ID: 12757053
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.
Abulfathi AA; Donald PR; Adams K; Svensson EM; Diacon AH; Reuter H
Br J Clin Pharmacol; 2020 Nov; 86(11):2123-2132. PubMed ID: 32470182
[TBL] [Abstract][Full Text] [Related]
18. Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations.
Wang W; Li S; Ge Q; Guo H; Shang Y; Ren W; Wang Y; Xue Z; Lu J; Pang Y
Ann Clin Microbiol Antimicrob; 2022 Nov; 21(1):48. PubMed ID: 36335391
[TBL] [Abstract][Full Text] [Related]
19. Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.
Kibleur Y; Brochart H; Schaaf HS; Diacon AH; Donald PR
Clin Drug Investig; 2014 Apr; 34(4):269-76. PubMed ID: 24488376
[TBL] [Abstract][Full Text] [Related]
20. Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012.
Zhang X; Liu L; Zhang Y; Dai G; Huang H; Jin Q
Antimicrob Agents Chemother; 2015 Feb; 59(2):1320-4. PubMed ID: 25421465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
